Show results for
Refine by
Glucose Monitoring System Articles & Analysis
12 news found
Alertgy is excited to announce that we have moved to a new facility! We are still in the process of organizing our new headquarters, but we wanted to share with you our newly expanded capabilities and our progress thus far. Alertgy is also pleased to announce that it has been awarded a Developers Agreement between Alertgy Inc. and SEMI – Flextech. SEMI is the global industry association ...
ByAlertgy
Alertgy, the biotech startup that’s in the race to be the first company to develop an entirely non-invasive glucose monitoring system is proud to welcome a new hire in the Engineering Department: Benjamin Freer joins Alertgy as Director of Engineering/Principal Sensor Engineer. ...
ByAlertgy
Key Research Survey Findings: 52 percent of healthcare providers agreed motivation is a major barrier to patients adhering to blood glucose monitoring compared to only 10 percent of people with diabetes who agreed motivation is a major barrier. ...
ByLifeScan
LifeScan, a world leader in blood glucose monitoring and digital health technology, is committed to supporting resources that help promote diabetes education and improved health management, including our most recent sponsorship of The Diabetes Way website, offering a straight-forward educational resource – even for those questions you were afraid to ask. Along with educational content ...
ByLifeScan
Prior to that, while at Abbott he led one of the most successful medical device launches in history with the introduction of the FreeStyle Libre Diabetes Continuous Glucose Monitor system. At the start of his career, Mr. Nock held leadership positions at Danaher and Thermo Fisher Scientific. ...
(NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2021. ...
(NYSE-American: SENS), a medical technology company focused on the development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its fourth quarter and full year 2021 financial results after market close on Tuesday, March 1, 2022. ...
(NYSE American: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced that it had made equity grants to new employees under its 2019 Inducement Plan (the “Plan”) in accordance with NYSE American ...
(NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational and financial business updates. ...
(NYSE American: SENS) a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced it received CE mark of the Eversense® NOW Remote Monitoring App for the Android Operating System. ...
(NASDAQ: DXCM; $38 billion market cap), a provider of continuous glucose monitoring systems, from June 2001 to September 2007. Mr. Blickenstaff was recognized as the 2020 Director of the Year by The Corporate Directors Forum for his outstanding performance in the boardroom and behind the scenes. ...
Zucara Therapeutics Inc., a life sciences company developing the first once-daily therapeutic to prevent hypoglycemia in people with Type 1 diabetes and other types of insulin-dependent diabetes, presented new findings today at the 55th Annual Meeting of the European Association for the Study of Diabetes on September 16-20, 2019 in Barcelona. The company recently undertook research to determine ...